These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 12436445

  • 1. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L.
    Cancer; 2002 Dec 01; 95(11):2373-9. PubMed ID: 12436445
    [Abstract] [Full Text] [Related]

  • 2. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M, Demertzis N, Iakovidou I, Kottakis S.
    Anticancer Res; 2007 Dec 01; 27(2):1143-7. PubMed ID: 17465254
    [Abstract] [Full Text] [Related]

  • 3. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA.
    Cancer; 2006 May 01; 106(9):2005-11. PubMed ID: 16565971
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B, Leithner A, Bauernhofer T, Windhager R, Guelly C, Regauer S, Beham A.
    Histopathology; 2006 Dec 01; 49(6):576-81. PubMed ID: 17163842
    [Abstract] [Full Text] [Related]

  • 5. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 01; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Oct 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 7. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP, Matthews KS, Kimball KJ, Conner MG, Baker AC, Barnes MN.
    Reprod Sci; 2008 Sep 01; 15(7):673-7. PubMed ID: 18492696
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
    Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, Siu LL.
    J Clin Oncol; 2005 Jan 20; 23(3):585-90. PubMed ID: 15659505
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM.
    Cancer; 2003 Aug 15; 98(4):758-64. PubMed ID: 12910520
    [Abstract] [Full Text] [Related]

  • 11. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 15; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 12. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A.
    Cancer Res; 2009 Jun 15; 69(12):5099-107. PubMed ID: 19509233
    [Abstract] [Full Text] [Related]

  • 13. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C.
    Cancer Lett; 2009 Jan 08; 273(1):70-9. PubMed ID: 18809244
    [Abstract] [Full Text] [Related]

  • 14. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, Pichon F, Frappaz D, Chatelut E, Opolon P, Hain S, Boderet F, Bosq J, Emile JF, Le Deley MC, Capdeville R, Vassal G, Innovative Therapies for Children with Cancer European Consortium.
    Eur J Cancer; 2009 Sep 08; 45(13):2342-51. PubMed ID: 19362466
    [Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 16. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F, Terreni MR, Longoni M, Boari N, Mortini P, Doglioni C, Riva P.
    Oncol Rep; 2007 Jul 15; 18(1):249-52. PubMed ID: 17549375
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
    Prunotto M, Bosco M, Daniele L, Macri' L, Bonello L, Schirosi L, Rossi G, Filosso P, Mussa B, Sapino A.
    Lung Cancer; 2009 May 15; 64(2):244-6. PubMed ID: 19041155
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
    Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ.
    Gynecol Oncol; 2010 May 15; 117(2):248-54. PubMed ID: 20189232
    [Abstract] [Full Text] [Related]

  • 20. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
    Wcislo G, Szarlej-Wcislo K, Szczylik C.
    J Cancer Res Clin Oncol; 2007 Aug 15; 133(8):533-8. PubMed ID: 17453242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.